Fox Chase Cancer Center Researcher Shows Biweekly Dose of TAS-102 Reduces Toxicity and Remains Effective for Treatment of Colorectal Cancer

Christopher Cann
Christopher G. Cann, MD, Assistant Professor in the Department of Hematology/Oncology at Fox Chase Cancer Center

PHILADELPHIA (June 5, 2025) — Patients with metastatic colorectal cancer who were treated with a biweekly dose of trifluridine-tipiracil (TAS-102) saw similar treatment effectiveness and reduced toxicity compared with treatment using standard dosing schedules, according to a recent study in The Oncologist that was co-authored by a Fox Chase Cancer Center physician. 

TAS-102, also known by the brand name Lonsurf, is a chemotherapy drug used to treat metastatic colorectal cancer in patients whose cancer is resistant to first- and second-line therapies and who cannot be treated with surgery. The standard treatment schedule is twice daily dosing on days 1 through 5 and then again on days 8 through 12 of a 28-day chemotherapy cycle. 

“We’ve seen that this typical dosing schedule frequently causes significant bone marrow suppression, and patients often require dose reductions or treatment delays to recover. In other cases, patients have to use a medication called G-CSF, which helps to increase white blood cell counts. Use of this medication, however, can also cause side effects such as bone pain and other more serious complications,” said Christopher G. Cann, MD, lead author on the study and Assistant Professor in the Department of Hematology/Oncology at Fox Chase.

The retrospective study, which Cann conducted with researchers from several other institutions, is the first of its kind in the United States. The researchers examined 61 patients with metastatic colorectal cancer who were treated with a biweekly dose of TAS-102. Treatment on this new schedule began on days 1 through 5 and continued on days 15 through 19 within a 28-day cycle. 

The study found that the alternative biweekly dosing not only remained effective at treating colorectal cancer, but also resulted in less treatment-related bone marrow suppression and dose delays overall compared to patients given standard dosing. Additionally, no patients treated with biweekly dosing required the use of G-CSF or developed neutropenic fever, which can be life threatening.

“These findings provide us an alternative way to dose chemotherapy that maintains efficacy but reduces the toxicity of the treatment,” said Cann. “This dosing schedule may be most useful for older patients or patients who have developed chemotherapy related toxicities. This schedule also allows us to combine TAS-102 with other effective chemotherapies more easily due to reduced toxicity.”

Cann said that although the results of the study are promising, additional prospective, multicenter data will be required to further validate findings and expand the use of biweekly dosing schedules for TAS-102.

The study, “Biweekly Dosing of TAS-102 Reduces Rates of Myelosuppression While Maintaining Efficacy in Patients with Metastatic Colorectal Cancer,” was published in The Oncologist.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427